
    
      This is an open-label, single arm pilot study to explore clinical and biochemical endpoints
      of pericarditis symptomatology and to collect data to assess inter- and intra-subject
      variability on both at-baseline and on-treatment parameters. This study consists of 5
      distinct Parts, and all subjects will be treated with once-weekly subcutaneously
      (SC)-administered injections of KPL-914.There is an optional 18-week extension period.
    
  